These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3296209)

  • 1. Cytosine arabinoside for induction, salvage, and consolidation therapy of adult acute lymphoblastic leukemia.
    Stryckmans P; De Witte T; Bitar N; Marie JP; Suciu S; Solbu G; Debusscher L; Bury J; Peetermans M; Andrien JM
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):67-72. PubMed ID: 3296209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Jehn U; Heinemann V
    Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone].
    Marín P; Grañena A; Carreras E; Ribera JM; Rozman C
    Sangre (Barc); 1984; 29(6):987-92. PubMed ID: 6598237
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
    Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A
    J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adult acute lymphoblastic leukemia: preliminary results of the LAL-86 protocol].
    Ribera JM; Grañena A; Rozman C; Urbano-Ispizua A; Bladé J; Carreras E; Cervantes F; Marín P; Sierra J; Nomdedeu B
    Sangre (Barc); 1990 Feb; 35(1):26-32. PubMed ID: 2333581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
    Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of 218 adult acute lymphoblastic leukemias.
    Fiere D; Extra JM; David B; Witz F; Vernand JP; Gastaut JA; Dauriac C; Pris J; Marty M
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):64-6. PubMed ID: 3296208
    [No Abstract]   [Full Text] [Related]  

  • 12. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
    Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
    Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
    Willemze R; Zijlmans JM; den Ottolander GJ; Kluin-Nelemans JC; Falkenburg JH; Starrenburg CW; van der Burgh JF; Fibbe WE
    Ann Hematol; 1995 Feb; 70(2):71-4. PubMed ID: 7880926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature.
    Peters WG; Willemze R; Colly LP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):86-91. PubMed ID: 3473687
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome by allogeneic bone marrow transplantation.
    Conter V; D'Angelo P; Rizzari C; Jankovic M; Dampier C; Masera G; Johnson FL
    Bone Marrow Transplant; 1996 Feb; 17(2):287-9. PubMed ID: 8640182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia. Potential selective effect in T-cell leukemia.
    Lauer SJ; Pinkel D; Buchanan GR; Sartain P; Cornet JM; Krance R; Borella LD; Casper JT; Kun LE; Hoffman RG
    Cancer; 1987 Nov; 60(10):2366-71. PubMed ID: 3499211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.